All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Why the initial efficacy observed with melflufen + dexamethasone has not translated into improved overall survival (OS) in the OCEAN phase III trial.
Featured:
Pieter SonneveldDuring the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Pieter Sonneveld, Erasmus MC, Rotterdam, NL. We asked, Why the initial efficacy observed with melflufen + dexamethasone has not translated into improved overall survival (OS) in the OCEAN phase III trial.
OCEAN phase III trial: Why the initial efficacy observed with melflufen + dex has not improved OS
In this video, Sonneveld discusses results from the OCEAN phase III (NCT03151811), multi-center trial, comparing melphalan flufenamide (melflufen) + dexamethasone versus pomalidomide + dexamethasone.
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?